13F-HR filed by Lynx1 Capital Management LP
Lynx1 Capital Management LP filed this 13F-HR for the quarter ended 2023-06-30, filed 2023-08-14, with 18 holding rows worth $152,625,429.
- Accession
- 0001892688-23-000073
- Filer
- CIK 1910456
- Filed
- 2023-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2023
A holdings report, 18 entries on the cover page, a total value of $152,625,429 stated on the cover page (in dollars after the unit check, H1), rows summing to $152,625,429 with VALUE read as dollars as filed, 13F file number 028-22151. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerLynx1 Capital Advisors LLC028-22145
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MERUS N V | N5749R100 | COM | 1,152,525 | $30,345,983 | dollars as filed | |
| CABALETTA BIO INC | 12674W109 | COMMON STOCK | 2,181,377 | $28,161,577 | dollars as filed | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 2,670,472 | $27,452,452 | dollars as filed | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 1,205,050 | $13,195,298 | dollars as filed | |
| Tscan Therapeutics Inc | 89854M101 | COM | 5,224,600 | $13,061,500 | dollars as filed | |
| GH RESEARCH PLC ORDINARY SHARES | G3855L106 | Stock | 969,374 | $11,501,623 | dollars as filed | |
| PARDES BIOSCIENCES INC | 69945Q105 | COM | 3,902,434 | $7,063,406 | dollars as filed | |
| THESEUS PHARMACEUTICALS INC | 88369M101 | COM | 757,009 | $7,062,894 | dollars as filed | |
| KINNATE BIOPHARMA INC | 49705R105 | COM | 2,048,736 | $6,207,670 | dollars as filed | |
| NEOLEUKIN THERAPEUTICS INC | 64049K104 | COM | 3,094,554 | $2,568,480 | dollars as filed | |
| PIERIS PHARMACEUTICALS INC | 720795103 | COM | 9,775,849 | $1,617,903 | dollars as filed | |
| CULLINAN THERAPEUTICS INC | 230031106 | COM | 115,063 | $1,238,078 | dollars as filed | |
| PASSAGE BIO INC | 702712100 | COM | 1,167,343 | $1,098,820 | dollars as filed | |
| STRUCTURE THERAPEUTICS INC COMP | 86366E106 | EQUITY | 23,000 | $956,110 | dollars as filed | |
| ATHIRA PHARMA INC | 04746L104 | COM | 193,573 | $571,040 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 21,225 | $321,347 | dollars as filed | |
| COMPASS PATHWAYS PLC | 20451W101 | SPONSORED ADS | 20,114 | $166,544 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J101 | ADR | 18,265 | $34,704 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001892688-23-000073 | this filing | 2023-08-14 | acceptance time not in the bulk data set |